Drugs targeting AKT have been shown to induce apoptosis and suppress tumor growth15, whereas the downregulation of AKT phosphatase PHLPP1 is associated with chemoresistance in CRC16, thus indicating that AKT is an important therapeutic target in CRC treatment. The gene discussed is AKT1; the disease is colorectal carcinoma.